- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S4054
| Related Targets | Adrenergic Receptor Estrogen/progestogen Receptor GPR Glucocorticoid Receptor ACE RAAS Progesterone Receptor Opioid Receptor PGES THR |
|---|---|
| Other Androgen Receptor Inhibitors | Bavdegalutamide (ARV-110) RU58841 Galeterone EPI-001 Cyproterone Acetate 3,3'-Diindolylmethane GSK-2881078 Chlormadinone acetate GDC-2992 JNJ-63576253 (TRC-253) |
|
In vitro |
DMSO
: 83 mg/mL
(199.24 mM)
Ethanol : 27 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 416.57 | Formula | C24H32O4S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 52-01-7 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C | ||
| Targets/IC50/Ki |
Androgen Receptor
77 nM
|
|---|---|
| In vitro |
Spironolactone is a strong AR antagonist (IC50 ~ 77 nM), a weak GR antagonist (IC50 ~ 2.4 μM), and a weak PR agonist (EC50 ~ 740 nM). This compound inhibits androstanolone binding in rat prostate nuclei and androstanolone specific binding in rat prostate cytosol.
|
| In vivo |
Spironolactone (1 mg/day) exerts anti-androgenic activity in rats. A single pretreatment of this compound (1 mg/rat) inhibits specific and saturable uptake of hormone into prostate induced by tracer dose administration of [3H]testosterone.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06021860 | Not yet recruiting | Edema Due to Heart Failure or Cirrhosis |
CMP Development LLC |
June 2024 | Phase 4 |
| NCT06204640 | Not yet recruiting | Atrial Fibrillation Recurrent |
University Hospital Caen |
March 1 2024 | Phase 3 |
| NCT05807139 | Recruiting | Alcohol Use Disorder |
National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC) |
July 13 2023 | Phase 1 |
| NCT05092984 | Recruiting | Rheumatoid Arthritis |
University Hospital Strasbourg France |
June 22 2022 | Phase 3 |
| NCT04723862 | Recruiting | Hyperandrogenism|Polycystic Ovary Syndrome|Puberty |
University of Virginia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
November 12 2021 | Early Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.